- Home
- APRE vs EVOK Comparison
APRE vs EVOK Comparison
Compare APRE & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- EVOK
- Stock Information
- Founded
- APRE 2006
- EVOK 2007
- Country
- APRE United States
- EVOK United States
- Employees
- APRE N/A
- EVOK N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- EVOK Health Care
- Exchange
- APRE Nasdaq
- EVOK Nasdaq
- Market Cap
- APRE 8.3M
- EVOK 7.6M
- IPO Year
- APRE 2019
- EVOK 2013
- Fundamental
- Price
- APRE $1.39
- EVOK $10.73
- Analyst Decision
- APRE Strong Buy
- EVOK
- Analyst Count
- APRE 1
- EVOK 0
- Target Price
- APRE $20.00
- EVOK N/A
- AVG Volume (30 Days)
- APRE 141.8K
- EVOK 24.9K
- Earning Date
- APRE 11-07-2025
- EVOK 11-07-2025
- Dividend Yield
- APRE N/A
- EVOK N/A
- EPS Growth
- APRE N/A
- EVOK N/A
- EPS
- APRE N/A
- EVOK N/A
- Revenue
- APRE $841,012.00
- EVOK $12,794,859.00
- Revenue This Year
- APRE N/A
- EVOK $57.38
- Revenue Next Year
- APRE N/A
- EVOK $59.57
- P/E Ratio
- APRE N/A
- EVOK N/A
- Revenue Growth
- APRE N/A
- EVOK 70.02
- 52 Week Low
- APRE $1.31
- EVOK $1.94
- 52 Week High
- APRE $5.00
- EVOK $9.88
- Technical
- Relative Strength Index (RSI)
- APRE 42.40
- EVOK 84.73
- Support Level
- APRE $1.31
- EVOK $4.50
- Resistance Level
- APRE $1.46
- EVOK $5.19
- Average True Range (ATR)
- APRE 0.09
- EVOK 0.30
- MACD
- APRE -0.01
- EVOK 0.40
- Stochastic Oscillator
- APRE 22.11
- EVOK 99.53
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.